Drug major Sun Pharma today said it has gotten the green signal from the US health regulator to market a generic version of 'Cymbalta', a capsule used for treatment of anxiety and depression, in the American market.
The company's subsidiary has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for generic duloxetine hydrochloride capsules in strengths of 20mg, 30 mg and 60 mg, Sun Pharmaceutical Industries said in a statement.
The generic duloxetine hydrochloride capsules are used for the treatment of major depressive disorder, generalised anxiety disorder and diabetic peripheral neuropathic pain, it said.
Annual sales of Cymbalta capsules amount to nearly $3 billion in the US, it added.
Shares of Sun Pharma today closed at Rs 2,272.15 on the Bombay Stock Exchange, up 0.11 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app